Once-weekly exenatide as a treatment for Type 2 diabetes

Marisa B. Schauerhamer, Holly Gurgle, Carrie Mcadam-Marx

Research output: Contribution to journalArticlepeer-review

Abstract

Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications. As the disease progresses, most patients require combination therapy to achieve glucose control targets. Exenatide once weekly (EQW) is a glucagon-like peptide-1 receptor agonist approved in the United States in 2012 for use as a second-line agent to treat Type 2 diabetes mellitus. EQW has shown reductions in HbA1c and weight without causing an increased risk of hypoglycemia. This review will summarize the current clinical trial, observational study, and pharmacoeconomic analyses evaluating EQW and its impact on HbA1c and weight..

Original languageEnglish (US)
Pages (from-to)611-626
Number of pages16
JournalExpert review of cardiovascular therapy
Volume13
Issue number6
DOIs
StatePublished - Jun 1 2015

Keywords

  • HbA1c
  • clinical trial
  • diabetes mellitus
  • exenatide
  • observational study . pharmacoeconomic evaluation
  • weight

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Once-weekly exenatide as a treatment for Type 2 diabetes'. Together they form a unique fingerprint.

Cite this